Working closely with Maven Communications, we developed a 3D MOA animation for Novartis illustrating the mechanism of action of Sandostatin LAR. Sandostatin LAR is indicated for the treatment of patients with symptoms associated with functional gastroenteropancreatic neuroendocrine tumors.
LISTERINE ANTISEPTIC
By
admin
Listerine Antiseptic and its dental health benefits are featured in this animation work for Johnson & Johnson. We begin at an interior view of the mouth, showing brushing and flossing to remove plaque from the surface of the tooth. When Listerine Antiseptic is introduced for rinsing, the viewer is taken on an amusement park splash ride inside the mouth.
LISTERINE FLUORIDE
By
admin
The dental benefits of rinsing with Listerine Total Care are described in our latest animation project with Johnson & Johnson. To conceptualize the damage to tooth enamel from our eating habits, the hydroxyapatite rods making up the tooth enamel were given a level of fine surface detail reminiscent of an eroded canyon wall.
QLS-101 MOA
By
admin
The animation presents fine visual detail of the eye anatomy, including the sinuous path of the episcleral veins and the cross-sectional view of the retina that so closely resembles human anatomy, you would think you were examining someone’s actual eye. With this dynamic and detailed animation, healthcare providers, consumers, and investors can better understand how eye pressure is regulated and how Qlaris Bio is attempting to innovate in the field and address an unmet need in treating increased pressure inside the eye.
SONNET PLATFORM MOA
By
Jordan Maire
Sonnet BioTherapeutics requested an animation to help explain how their Fully Human Albumin Binding (FHAB) platform functions and the potential benefits of the platform over existing anti-tumor therapies. With vivid colors and key lighting details, the FHAB is clearly the star of the show in this animation.
VOXELOTOR AN INVESTIGATIONAL DRUG FOR SICKLE CELL DISEASE
By
admin
In collaboration with Global Blood Therapeutics, our folks here at XVIVO created this medical animation to illustrate the mechanism of action of a potential drug candidate for the treatment of sickle cell disease (SCD).
IDIOPATHIC PULMONARY FIBROSIS AND THE EFFECTS OF TREATMENT
By
admin
The animation, developed in partnership with Wedgewood Communications, shows the mechanism of disease for IPF and the mechanism of action for the recently-approved agent OFEV (nintedanib) from Boehringer Ingelheim.
PALOVAROTENE MOA
By
Jordan Maire
Fibrodysplasia ossificans progressiva, or FOP, is an extremely rare and debilitating disorder, in which bone tissue gradually replaces soft tissue throughout the body, extending the skeleton and “freezing” patients into position.
APOPTOSIS AND BCL-2
By
admin
ABT-199/GDC-0199 is a small molecule drug in co-development by Abbvie and Genentech for the selective inhibition of BCL-2, a key regulator of cellular apoptosis. BCL-2, part of the larger BCL-2 family, is responsible for the sequestration of pro-apoptotic proteins along the mitochondrial membrane. Displacement of these proteins from BCL-2 in cancerous cells may prime these cells for apoptosis.
GLEEVEC (IMATINIB) MOA
By
Jordan Maire
Kit is a receptor tyrosine kinase that activates of a number of pathways that direct cell proliferation, survival, and apoptosis. Mutations in Kit that result in constitutive oligomerization in the absence of ligand can drive continuous oncogenic signaling.